Status:
COMPLETED
Compliance With Treatment For Patients With Hyperlipidemia
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Hyperlipidemia
Eligibility:
All Genders
18-100 years
Brief Summary
It is a prospective observational study. Patients will be high risk patients (for developing cardiovascular events) that are treated with a statin. Patients will be enrolled at a normal clinic visit ...
Detailed Description
Consecutive patient sampling
Eligibility Criteria
Inclusion
- Aged 18 years or older and able to understand and sign the informed consent form.
- Patients diagnosed with hyperlipidemia and a very high risk developing cardiovascular disease prescribed statin treatment according to clinical praxis and the recommendations set forth in the MPA national guideline for treatment of hyperlipidemia.
Exclusion
- Patients contraindicated for statin treatment according to market authorization for these drugs should be excluded from the study.
- Patients participating in other clinical trials or non-interventional studies.
Key Trial Info
Start Date :
February 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
259 Patients enrolled
Trial Details
Trial ID
NCT00828945
Start Date
February 1 2009
End Date
March 1 2011
Last Update
February 21 2021
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Åkersberga, Sweden, 184 27
2
Pfizer Investigational Site
Forshaga, Sweden, 667 32
3
Pfizer Investigational Site
Gothenburg, Sweden, 405 30
4
Pfizer Investigational Site
Gothenburg, Sweden, 415 10